Literature DB >> 7579458

Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions.

P G Elmberger1, M D Lozano, D D Weisenburger, W Sanger, W C Chan.   

Abstract

Anaplastic large cell lymphoma (ALCL) and Hodgkin's disease (HD) have some pathologic and immunohistochemical similarities, and a histogenetic relationship between them has been suggested by some investigators. By cytogenetic study, the t(2;5)(p23;q35) translocation appears to be unique for ALCL. The breakpoints of the t(2;5)(p23;q35) have recently been cloned and are reported to involve a novel tyrosine kinase gene, anaplastic lymphoma kinase (alk), on chromosome 2 and the nucleophosmin gene (npm) on chromosome 5. Therefore, we studied the frequency of npm-alk translocation in ALCL using a reverse transcriptase-polymerase chain reaction (RT-PCR) assay. We also studied HD and a variety of reactive lymphoid lesions since there is contradictory information in the literature on the occurrence of the npm-alk rearrangement in HD. We detected npm-alk hybrid mRNA in 8 of 22 cases of ALCL (36%), but none of the 21 cases of HD or the 11 cases with reactive lesions contained amplifiable template. All positive ALCL had the T or indeterminate phenotype and occurred in young adults or children. There was very good correlation between a cytogenetically detectable t(2;5) and a positive signal by RT-PCR. Our results indicate a selective but relatively infrequent association between the t(2;5) and ALCL of T or indeterminate phenotype, not shared with HD or reactive hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579458

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Creating cancer translocations in human cells using Cas9 DSBs and nCas9 paired nicks.

Authors:  Benjamin Renouf; Marion Piganeau; Hind Ghezraoui; Maria Jasin; Erika Brunet
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.

Authors:  S Pittaluga; I Wlodarska; K Pulford; E Campo; S W Morris; H Van den Berghe; C De Wolf-Peeters
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

3.  Evaluation of enrichment techniques for mass spectrometry: identification of tyrosine phosphoproteins in cancer cells.

Authors:  Jonathan A Schumacher; David K Crockett; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

4.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

Authors:  B Falini; B Bigerna; M Fizzotti; K Pulford; S A Pileri; G Delsol; A Carbone; M Paulli; U Magrini; F Menestrina; R Giardini; S Pilotti; A Mezzelani; B Ugolini; M Billi; A Pucciarini; R Pacini; P G Pelicci; L Flenghi
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

5.  Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation.

Authors:  D Raepple; F von Lintig; T Zemojtel; M Duchniewicz; A Jung; M Lübbert; G R Boss; J S Scheele
Journal:  Ann Hematol       Date:  2008-09-11       Impact factor: 3.673

6.  Metastatic anaplastic large cell lymphoma of the oral cavity.

Authors:  Parviz Deyhimi; Forouz Keshani; Faezeh Azmoudeh; Zahra Hashemzadeh
Journal:  Dent Res J (Isfahan)       Date:  2012-12

7.  Cancer translocations in human cells induced by zinc finger and TALE nucleases.

Authors:  Marion Piganeau; Hind Ghezraoui; Anne De Cian; Lionel Guittat; Mark Tomishima; Loic Perrouault; Oliver René; George E Katibah; Lei Zhang; Michael C Holmes; Yannick Doyon; Jean-Paul Concordet; Carine Giovannangeli; Maria Jasin; Erika Brunet
Journal:  Genome Res       Date:  2013-04-08       Impact factor: 9.043

Review 8.  ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.

Authors:  Mingxiang Ye; Xinxin Zhang; Nan Li; Yong Zhang; Pengyu Jing; Ning Chang; Jianxiong Wu; Xinling Ren; Jian Zhang
Journal:  Oncotarget       Date:  2016-03-15

9.  Exome sequencing identified six copy number variations as a prediction model for recurrence of primary prostate cancers with distinctive prognosis.

Authors:  Jie Liu; Jiajun Yan; Ruifang Mao; Guoping Ren; Xiaoyan Liu; Yanling Zhang; Jili Wang; Yan Wang; Meiling Li; Qingchong Qiu; Lin Wang; Guanfeng Liu; Shanshan Jin; Liang Ma; Yingying Ma; Na Zhao; Hongwei Zhang; Biaoyang Lin
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.